Mobile low-dose CT screening for lung cancer in younger adults
Lung B.A.S.E.S 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Assessing Incidence and Stage of Lung Cancer Diagnosis in Subjects Ages 40-54 With a 30 Pack Year History or More Within North and South Carolina
This study is testing if a mobile low-dose CT scan can help find lung cancer earlier in younger adults aged 40-54 who have a significant history of smoking.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1160 (estimated) |
| Ages | 40 Years to 54 Years |
| Sex | All |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Charlotte, North Carolina) |
| Trial ID | NCT04577599 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of mobile low-dose computed tomography (LDCT) screening for lung cancer in individuals aged 40-54 with a significant smoking history. It aims to determine the lung cancer diagnosis rate at the first screening and subsequent screenings, while also assessing the impact of demographic and socioeconomic factors on screening outcomes. The study plans to enroll approximately 1160 participants to identify 174 evaluable subjects, focusing on a high-risk population in North and South Carolina.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 40-54 with a smoking history of 30 pack years or more, who are currently smoking or have quit within the last 15 years.
Not a fit: Patients with a known diagnosis of lung cancer in the past 5 years or contraindications to low-dose CT scans will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of lung cancer in younger high-risk individuals, potentially improving survival rates.
How similar studies have performed: Previous studies have shown that low-dose CT screening can significantly improve lung cancer detection rates in older populations, suggesting potential success in this younger demographic.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject must meet all the following applicable inclusion criteria to participate in this study: 1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age 40-54 years at the time of consent. 3. A positive smoking history of greater/equal to 30 pack years and they are either currently smoking or have quit within the last 15 years. 4. Ability to read and understand the English and/or Spanish language. 5. Ability to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: * Subjects meeting any of the criteria below may not participate in the study: 1. Known diagnosis of lung cancer in the past 5 years. 2. Any known contraindication to having a low-dose CT Scan. 3. Known pregnancy.
Where this trial is running
Charlotte, North Carolina
- Levine Cancer Institute — Charlotte, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Daniel Carrizosa, MD — Lci
- Study coordinator: Darcy Doege, RN
- Email: Darcy.Doege@atriumhealth.org
- Phone: 913-424-6431
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.